Hematopoietic Stem Cell TransplantationCord Blood Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsHematopoietic Stem CellsStem Cell TransplantationGraft vs Leukemia EffectTransplantation, AutologousTissue DonorsTransplantation ChimeraPeripheral Blood Stem Cell TransplantationGraft vs Tumor EffectBone Marrow TransplantationTreatment OutcomeLeukemiaMyeloablative AgonistsRetrospective StudiesHistocompatibilityRecurrenceBusulfanChimerismHistocompatibility TestingWhole-Body IrradiationGraft SurvivalVidarabineAllograftsStem CellsHematologic DiseasesLeukemia, Myeloid, AcuteMyelodysplastic SyndromesFetal BloodSiblingsHLA AntigensSurvival RateImmunosuppressive AgentsRemission InductionLymphocyte TransfusionAcute DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsHepatic Veno-Occlusive DiseaseCytomegalovirus InfectionsTransplantation ImmunologySurvival AnalysisT-LymphocytesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantation, IsogeneicAnemia, AplasticCombined Modality TherapyFollow-Up StudiesLymphocyte DepletionMinor Histocompatibility AntigensLeukemic InfiltrationCystitisDisease-Free SurvivalAntigens, CD34HematopoiesisFlow CytometryOpportunistic InfectionsHematopoietic Stem Cell MobilizationMultiple MyelomaSevere Combined ImmunodeficiencyRisk FactorsAntilymphocyte SerumNeoplasm, ResidualSalvage TherapyCyclophosphamideLymphoproliferative DisordersCytomegalovirusMice, Inbred C57BLBone Marrow CellsIsoantigensImmunosuppressionLiver TransplantationImmunocompromised HostCell DifferentiationBronchiolitis ObliteransBlood Group IncompatibilityMycosesLeukemia, MyeloidPrognosisPhotopheresisFatal OutcomeGraft RejectionProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsGanciclovirPrimary MyelofibrosisUnrelated DonorsSurvivorsCell TransplantationLiving DonorsCell LineageMesenchymal Stem Cell TransplantationChronic DiseaseCyclosporineCells, CulturedCytarabine